|1.||Jones, Hendrée E: 15 articles (11/2015 - 05/2003)|
|2.||Jansson, Lauren M: 14 articles (01/2014 - 07/2005)|
|3.||Porte, Robert J: 12 articles (07/2015 - 01/2006)|
|4.||Kaltenbach, Karol: 11 articles (01/2015 - 01/2007)|
|5.||Fischer, Gabriele: 11 articles (11/2012 - 01/2003)|
|6.||O'Grady, Kevin E: 9 articles (01/2014 - 07/2005)|
|7.||Nobili, Valerio: 7 articles (08/2015 - 11/2006)|
|8.||Heil, Sarah H: 7 articles (11/2013 - 12/2010)|
|9.||Martin, Peter R: 6 articles (05/2015 - 12/2010)|
|10.||Sanyal, Arun J: 6 articles (01/2013 - 06/2005)|
|1.||Chronic Hepatitis B
06/21/2014 - "Introduction of nucleos(t)ide analogues (NAs) for oral antiviral therapy has dramatically improved the clinical outcome in patients with chronic hepatitis B (CHB). "
07/01/2011 - "Drug resistance is a major limitation for the long-term efficacy of antiviral therapy with nucleos(t)ide analogues (NAs) in chronic hepatitis B (CHB). "
02/14/2015 - "The development of effective nucleos(t)ide analogs (NAs) against hepatitis B virus (HBV) has improved the outcome of patients with chronic hepatitis B (CHB). "
01/01/2014 - "Oral nucleos(t)ide analogs (NAs) are effective in suppressing hepatitis B virus (HBV) replication in treatment naïve chronic hepatitis B (CHB) patients. "
10/01/2013 - "Treatment for chronic hepatitis B has improved drastically with the use of nucleot(s)ide analogues (NAs). "
10/01/2012 - "Change in Adipo-IR at week 16 was not associated with changes in any histological parameters at week 96, but improvement in Adipo-IR at week 96 was significantly associated with improvement in ballooning (P = 0.03), fibrosis (P = 0.004), and NAS (P = 0.01). "
12/01/1996 - "Our results confirm Hrubec and Omenn's conclusion that there was significantly greater concordance in MZ twins-pairs for alcoholic psychosis and cirrhosis in the NAS-NRC twins, and concordance rates remained similar to those reported 16 years earlier. "
01/01/2009 - "The primary outcome measure is defined as either an improvement in NAS by 2 or more in at least two NAS features, or a post-treatment NAS of 3 or less, and improvement in hepatocyte ballooning by 1 or more, and no worsening of fibrosis. "
08/01/2015 - "Moreover, the study of correlation between all stages of liver biopsy (CRN criteria) and the grade of retinopathy showed a positive correlation with fibrosis (r = 0.31) and an NAS score (r = 0.28). "
12/01/2015 - "When our NAS plus fibrosis system was used, more patients were recognized and the sensitivity increased. "
04/01/1991 - "NaS was found to have tumor promoting activity, showing a positive response at the 5 and 3% dose levels, with significantly greater activity at the higher dose. "
05/01/2007 - "In conclusion, it seems that the field of extracellular NAs has great potential to be exploited by the development of minimally-invasive diagnostic, prognostic and predictive assays for cancer if it is ensured that relevant and adequate controls are included in all studies."
04/01/2015 - "Cancer risk assessment foundation unraveling: new historical evidence reveals that the US National Academy of Sciences (US NAS), Biological Effects of Atomic Radiation (BEAR) Committee Genetics Panel falsified the research record to promote acceptance of the LNT."
04/01/2015 - "Thus, the linearity model used in cancer risk assessment was based on ideology rather than science and originated with the recommendation of the NAS BEAR Committee Genetics Panel. "
10/01/2014 - "In this article, I show why the basis for the population risk adjustment that the NAS recommended is correct-that current population cancer risk estimates, whether they are derived from animal bioassays or from human epidemiologic studies, likely provide estimates of the median with respect to human variation, which in turn must be an underestimate of the mean. "
08/01/2010 - "Only lobular inflammation improved significantly (P for the modified Brunt score = 0.011, P for NAS = 0.005). "
01/01/2014 - "Serum CK18-F levels showed a positive correlation with histologic steatosis (ρ = 0.271, P = 0.0033), inflammation (ρ = 0.353, P = 0.0005), ballooning (ρ = 0.372, P = 0.0001), and the total NAS (ρ = 0.474, P = 2.68 × 10-7). "
01/01/2014 - "NAS scoring system has good overall inter- and intra-observer agreement, but more attention should be given to defining the hepatocyte ballooning and lobular inflammation, and training the pathologists to improve the accuracy of pathology reports."
07/01/2012 - "Histological improvement was noted in NAS (P < 0.01) and individual components, including steatosis (P < 0.01), ballooning degeneration (P < 0.01), and lobular inflammation (P = 0.02). "
09/01/2010 - "The Spearman correlation coefficient between the NAS inflammation subscore and serum B12 concentration was 0.02. "
|5.||Neonatal Abstinence Syndrome
03/01/2015 - "To evaluate the efficacy of a universal maternal drug testing protocol for all mothers in a community hospital setting that experienced a 3-fold increase in neonatal abstinence syndrome (NAS) over the previous 5 years. "
03/01/2016 - "This study examined the effects of prenatal alcohol exposure (PAE) on the incidence and severity of neonatal abstinence syndrome (NAS). "
05/01/2015 - "This study determined the influence of prematurity on the manifestation and treatment of neonatal abstinence syndrome (NAS). "
01/01/2015 - "To study the incidence and patient characteristics of Neonatal Abstinence Syndrome (NAS) in infants who were born to opioid addicted mothers and required NICU admission over the three year period. "
09/01/2013 - "Retrospective, uncontrolled study which evaluates different therapies of neonatal abstinence syndrome (NAS) in preterm and term neonates. "
|1.||Non-alcoholic Fatty Liver Disease
|2.||Morphine (MS Contin)
|10.||Clonidine (ST 155)
|4.||Heterologous Transplantation (Xenotransplantation)